DE20115753U1 - Soluble collagens - Google Patents
Soluble collagensInfo
- Publication number
- DE20115753U1 DE20115753U1 DE20115753U DE20115753U DE20115753U1 DE 20115753 U1 DE20115753 U1 DE 20115753U1 DE 20115753 U DE20115753 U DE 20115753U DE 20115753 U DE20115753 U DE 20115753U DE 20115753 U1 DE20115753 U1 DE 20115753U1
- Authority
- DE
- Germany
- Prior art keywords
- collagens
- soluble
- acid buffer
- buffer system
- soluble collagens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
• ····
Lösliche KollageneSoluble collagens
Die Erfindung betrifft lösliche Kollagene auf der Basis nativer Rohstoffe tierischer Herkunft.The invention relates to soluble collagens based on native raw materials of animal origin.
Kollagene sind mit Bezug auf die Strukturen und die Molekülgrößen wesentliche Biopolymere, die im Hinblick auf ihre Isolierbarkeit vor allem in Häuten (Schwarten), Knorpeln und Knochen in faseriger Form vorkommen. Deren Grundeinheit, das Tropokollagen, liegt als miteinander wechselwirkende Trippelhelices vor. In den einzelnen Polypeptidketten finden sich hauptsächlich al- und oc2-Strukturen, die durch einen unterschiedlichen Glycosylisierungsgrad am Hydroxylysin in den al- und oc2-Ketten gekennzeichnet sind. In Schwarten, wie in der Schweinehaut, erkennt man außerdem eine ß-Anordnung. Auf der Basis der different angeordneten Trippelhelices sind die Kollagene grundsätzlich, sieht man von Mischformen ab, den Typen I, Il oder IM zuzuordnen. Im Typ I findet man al- und a2-Ketten im Verhältnis 2 : 1. Die Typen Il und III sind aus al-Einheiten zusammengesetzt. Konstitutiv sind diese Typen durch (?) (Glycin -X-Y)-Segmente in den Polypeptidketten miteinander vergleichbar. In der Tripeptideinheit steht X hauptsächlich für Hydroxyprolin und Y für Prolin.In terms of their structure and molecular size, collagens are important biopolymers which, in view of their isolability, occur in fibrous form primarily in skin (rinds), cartilage and bones. Their basic unit, tropocollagen, exists as interacting triple helices. The individual polypeptide chains mainly contain al and oc2 structures, which are characterized by a different degree of glycosylation at the hydroxylysine in the al and oc2 chains. In rinds, such as in pig skin, a ß arrangement can also be recognized. On the basis of the differently arranged triple helices, collagens can basically be assigned to types I, II or III, apart from mixed forms. In type I there are al and a2 chains in a ratio of 2:1. Types II and III are composed of al units. Constitutively, these types are comparable by (?) (glycine -X-Y) segments in the polypeptide chains. In the tripeptide unit, X mainly stands for hydroxyproline and Y for proline.
Die nativen Kollagene bestehen aus einem in wässrigen Systemen löslichen Makromolekülteil und einem unlöslichen fibrillären Teil. Die jeweiligen Anteile sind abhängig von Alter und Geschlecht der Tiere sowie von der Tierart. Zudem gibt es schlachtkörperteilspezifische Abhängigkeiten.The native collagens consist of a macromolecule part that is soluble in aqueous systems and an insoluble fibrillar part. The respective proportions depend on the age and sex of the animals as well as on the animal species. There are also carcass-specific dependencies.
Für den Einsatz in Kosmetika, Medicinal- und Pharmaprodukten steht bisher vor allem das in größeren Mengen anfallende unlösliche Material zur Verfügung. Seine Anwendung ist auf Grund der Unlöslichkeit aber stark eingegrenzt, weil die gewünschte Mischbarkeit mit wässrigen Phasen unter physiologischen Bedingungen nicht gegeben ist.Up to now, the insoluble material, which is produced in large quantities, has been the only material available for use in cosmetics, medicinal and pharmaceutical products. However, its use is severely limited due to its insolubility, as the desired miscibility with aqueous phases is not achieved under physiological conditions.
Bekannt ist die Gewinnung löslicher Kollagene mit pH-abhängigen Löslichkeitsprofilen von 7,6 bis 7,8 (DE 199 29 802), die jedoch nicht als physiologisch eingeordnet werden können. Es ist auch bekannt, Schlachtkörperteile durch Extrudieren soweit zu zerkleinern, dass eine rationelle Kollagengewinnung möglich ist. Dabei wird aber eine Temperatur des Extraktionsgutes erreicht, die zwangsläufig die native Struktur der Kollagene zerstört und bei kosmetischen, medicinalen und pharmakologischen Anwendungen der Kollagene zu einer allergenen Belastung führen kann.It is known that soluble collagens can be obtained with pH-dependent solubility profiles of 7.6 to 7.8 (DE 199 29 802), but these cannot be classified as physiological. It is also known that carcass parts can be minced by extrusion to such an extent that efficient collagen extraction is possible. However, this results in the extraction material reaching a temperature that inevitably destroys the native structure of the collagens and can lead to allergenic exposure in cosmetic, medicinal and pharmacological applications of the collagens.
Die Aufgabe der Erfindung ist es, in wässrigen Systemen lösliche Kollagene bereitzustellen, die in ihrer nativen Struktur erhalten und unter physiologischen Bedingungen applizierbar sind sowie ein erheblich reduziertes Allergiepotential besitzen.The object of the invention is to provide collagens that are soluble in aqueous systems and that retain their native structure, can be applied under physiological conditions and have a significantly reduced allergy potential.
A:\Losliche Kollagenell.rtf/Dr. Henze/14.09.§1,1 *2* • · · A:\Soluble collagenell.rtf/Dr. Henze/14.09.§1,1 *2* • · ·
: 1 : 1
I.I.
Die Aufgabe wird dadurch gelöst, dass das Rohmaterial mittels eines Schwerlastzerkleinerers auf Teilchengrößen von 4-10 mm homogenisiert und von Begleitstoffen befreitwird. The task is solved by homogenizing the raw material to particle sizes of 4-10 mm using a heavy-duty shredder and removing any accompanying substances.
Die löslichen Kollagene werden mittels Citrat-Säure-Puffersystem oder Acetat-Säure-Puffersystem pH-wertabhängig aus dem gereinigten Rückstand extrahiert. Die gewünschten Kollagene zeigen im Acetat-Säure-Puffersystem bei pH 3 im Elektropherogramm (Porengradientengel aus Polyacrylamid) Molekülbanden bei etwa 130 000, 160 000 und 280 000 Dalton. Die transversalen Protonen-Relaxationszeiten aus den niedrigauflösenden Protonen-Nuclear-Magnetoresonanz (LR-H1-NMR)-Spektren (Brukergerät "the minispec") liegen bei einer Einwaage von 3 mg/ml bei 1300 bis 1550 ms für Lösungen im Citrat-Säure-Pufferssystem (pH 4 bzw. 3). So charakterisierte lösliche Kollagene sind als Basis- oder Kombinationsmaterialien für den Einsatz in kosmetischen, medicinalen und pharmazeutischen Formulierungen ohne Löslichkeitseinschränkungen geeignet. Für Pharmaanwendungen ist der Aufbau von "drugdelivery-systems" - (DDS) mit verringertem Allergiepotential möglich.The soluble collagens are extracted from the purified residue using a citrate-acid buffer system or an acetate-acid buffer system, depending on the pH value. The desired collagens show molecular bands at around 130,000, 160,000 and 280,000 Dalton in the acetate-acid buffer system at pH 3 in the electropherogram (pore gradient gel made of polyacrylamide). The transverse proton relaxation times from the low-resolution proton nuclear magnetoresonance (LR-H 1 -NMR) spectra (Bruker device "the minispec") are 1300 to 1550 ms for solutions in the citrate-acid buffer system (pH 4 or 3) with a sample weight of 3 mg/ml. Soluble collagens characterized in this way are suitable as base or combination materials for use in cosmetic, medicinal and pharmaceutical formulations without solubility restrictions. For pharmaceutical applications, the construction of drug delivery systems (DDS) with reduced allergy potential is possible.
Die Erfindung soll an nachfolgenden Beispielen näher erläutert werden.The invention will be explained in more detail using the following examples.
In einem speziellen Schwerlastzerkleinerer werden 100 kg Schweineschwarte bei einer Betriebstemperatur von maximal 450C auf eine Teilchengröße von maximal 6 mm homogenisiert. Im Anschluss wird das Extraktionsgut in einer Kochsalzlösung gewaschen, um Fettbestandteile und Proteine abzutrennen. Waschen und das anschließende Zentrifugieren erfolgen in bekannter Weise.In a special heavy-duty shredder, 100 kg of pork rind is homogenized to a particle size of no more than 6 mm at an operating temperature of no more than 45 ° C. The extracted material is then washed in a saline solution to separate fat components and proteins. Washing and subsequent centrifugation are carried out in the usual way.
Das so erhaltene Zentrifugat wird mit der 7-fachen Menge an Pufferlösung entsprechend Acetat-Säure-Puffersystem oder Citrat-Säure-Puffersystem während einer Inkubationszeit von 24 Stunden weiter behandelt und danach erneut zentrifugiert. Das Zentrifugat enthält die löslichen Kollagene, die durch Zugabe einer konzentrierten Kochsalzslösung ausgefällt werden.
Die Aufreinigung des löslichen Kollagens erfolgt durch Dialyse. Nach einer Gefriertrocknung wird ein gut lagerfähiges in wässrigen Systemen lösliches Kollagen erhalten, dem entsprechend seiner vielfältigen Applikationsmöglichkeiten unterschiedliche Pharmaka mit z. B. antiinflammatorischen und/oder mikrobiociden Wirkungen zu gesetzt werden können.The centrifugate thus obtained is further treated with 7 times the amount of buffer solution corresponding to acetate-acid buffer system or citrate-acid buffer system during an incubation period of 24 hours and then centrifuged again. The centrifugate contains the soluble collagens, which are precipitated by adding a concentrated saline solution.
The soluble collagen is purified by dialysis. After freeze-drying, collagen is obtained that can be easily stored and is soluble in aqueous systems. Depending on its wide range of application possibilities, different pharmaceuticals with anti-inflammatory and/or microbicidal effects can be added to it.
Auf diese Weise werden aus 100 kg Schweineschwarte mit einem Gesamtkollagengehalt von 7,8 kg (davon 1,1 kg lösliches Kollagen) 690 g lösliches Kollagen in der durch die Puffersysteme bestimmten Qualität mit einem definiert verringerten Allergiepotential erhalten.In this way, 690 g of soluble collagen are obtained from 100 kg of pork rind with a total collagen content of 7.8 kg (of which 1.1 kg is soluble collagen) in the quality determined by the buffer systems with a defined reduced allergy potential.
Bei Verwendung von Schweineknochen sind die Schritte zur Isolierung der beschriebenen Kollagene in ihrer nativen Form jeweils identisch. Jedoch ist es bei diesem
Extraktionsgut erforderlich, nach seiner Homogenisierung im Schwerlastzerkleinerer wegen der höheren Mineralstoffanteile in Knochen eine Komplexierung vor allem von Calcium und Magnesium vorzuschalten.When using pig bones, the steps for isolating the described collagens in their native form are identical. However, in this case
After homogenization in a heavy-duty crusher, the material to be extracted must be complexed, particularly with regard to calcium and magnesium, due to the higher mineral content in bones.
A:\LiSsliche Kollageneil.rtf/Dr. Henze/14.09ji, i{A:\LiSsliche Kollageneil.rtf/Dr. Henze/14.09ji, i{
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20115753U DE20115753U1 (en) | 2001-09-14 | 2001-09-14 | Soluble collagens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20115753U DE20115753U1 (en) | 2001-09-14 | 2001-09-14 | Soluble collagens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE20115753U1 true DE20115753U1 (en) | 2002-01-10 |
Family
ID=7962103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE20115753U Expired - Lifetime DE20115753U1 (en) | 2001-09-14 | 2001-09-14 | Soluble collagens |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE20115753U1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097694A1 (en) * | 2002-05-21 | 2003-11-27 | Colltech Australia Ltd | Collagen and method for producing same |
| WO2008036393A1 (en) * | 2006-09-21 | 2008-03-27 | Purdue Research Foundation | Collagen preparation and method of isolation |
| US8518436B2 (en) | 2005-05-16 | 2013-08-27 | Purdue Research Foundation | Engineered extracellular matrices |
| US9315778B2 (en) | 2006-05-16 | 2016-04-19 | Purdue Research Foundation | Engineered extracellular matrices control stem cell behavior |
| US9867905B2 (en) | 2007-12-10 | 2018-01-16 | Purdue Research Foundation | Collagen-based matrices with stem cells |
| US9878071B2 (en) | 2013-10-16 | 2018-01-30 | Purdue Research Foundation | Collagen compositions and methods of use |
| US11739291B2 (en) | 2017-04-25 | 2023-08-29 | Purdue Research Foundation | 3-dimensional (3D) tissue-engineered muscle for tissue restoration |
| US11919941B2 (en) | 2015-04-21 | 2024-03-05 | Purdue Research Foundation | Cell-collagen-silica composites and methods of making and using the same |
| US12274808B2 (en) | 2014-08-27 | 2025-04-15 | Purdue Research Foundation | Collagen-based therapeutic delivery systems |
| US12280176B2 (en) | 2017-01-31 | 2025-04-22 | Geniphys, Inc. | Methods and compositions for matrix preparation |
| US12343450B2 (en) | 2020-01-27 | 2025-07-01 | Geniphys, Inc. | Biologic filler for restoring and regenerating tissue |
-
2001
- 2001-09-14 DE DE20115753U patent/DE20115753U1/en not_active Expired - Lifetime
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097694A1 (en) * | 2002-05-21 | 2003-11-27 | Colltech Australia Ltd | Collagen and method for producing same |
| CN100347192C (en) * | 2002-05-21 | 2007-11-07 | 科尔泰克澳大利亚有限公司 | Collagen and its preparation method |
| US8518436B2 (en) | 2005-05-16 | 2013-08-27 | Purdue Research Foundation | Engineered extracellular matrices |
| US9315778B2 (en) | 2006-05-16 | 2016-04-19 | Purdue Research Foundation | Engineered extracellular matrices control stem cell behavior |
| US8084055B2 (en) | 2006-09-21 | 2011-12-27 | Purdue Research Foundation | Collagen preparation and method of isolation |
| GB2455041B (en) * | 2006-09-21 | 2012-03-07 | Purdue Research Foundation | Collagen preparation and method of isolation |
| US8512756B2 (en) | 2006-09-21 | 2013-08-20 | Purdue Research Foundation | Collagen preparation and method of isolation |
| GB2455041A (en) * | 2006-09-21 | 2009-06-03 | Purdue Research Foundation | Collagen preparation and method of isolation |
| WO2008036393A1 (en) * | 2006-09-21 | 2008-03-27 | Purdue Research Foundation | Collagen preparation and method of isolation |
| US9867905B2 (en) | 2007-12-10 | 2018-01-16 | Purdue Research Foundation | Collagen-based matrices with stem cells |
| US11478574B2 (en) | 2013-10-16 | 2022-10-25 | Purdue Research Foundation | Collagen compositions and methods of use |
| US9878071B2 (en) | 2013-10-16 | 2018-01-30 | Purdue Research Foundation | Collagen compositions and methods of use |
| US12274808B2 (en) | 2014-08-27 | 2025-04-15 | Purdue Research Foundation | Collagen-based therapeutic delivery systems |
| US11919941B2 (en) | 2015-04-21 | 2024-03-05 | Purdue Research Foundation | Cell-collagen-silica composites and methods of making and using the same |
| US12280176B2 (en) | 2017-01-31 | 2025-04-22 | Geniphys, Inc. | Methods and compositions for matrix preparation |
| US11739291B2 (en) | 2017-04-25 | 2023-08-29 | Purdue Research Foundation | 3-dimensional (3D) tissue-engineered muscle for tissue restoration |
| US12398368B2 (en) | 2017-04-25 | 2025-08-26 | Purdue Research Foundation | 3-dimensional (3D) tissue-engineered muscle for tissue restoration |
| US12343450B2 (en) | 2020-01-27 | 2025-07-01 | Geniphys, Inc. | Biologic filler for restoring and regenerating tissue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gross et al. | Some factors involved in the fibrogenesis of collagen in vitro | |
| DE68917300T2 (en) | HEALING Wounds. | |
| DE3751887T2 (en) | EAST INDUCTIVE MEDIUM | |
| DE69727332T2 (en) | Preparations containing collagen, vitamin D3 and calcium to strengthen the bone | |
| DE69030956T2 (en) | Inhibition of the transforming growth factor to prevent the accumulation of extracellular matrix | |
| DE60003837T2 (en) | TETRAPEPTIDE THAT STIMULATES THE FUNCTIONAL ACTIVITY OF NEURONES, THIS CONTAINING PHARMACOLOGICAL AGENT AND ITS USE | |
| DE68912758T2 (en) | Wound healing. | |
| DE3885300T2 (en) | Healing Wounds. | |
| DE69129865T2 (en) | OSTEOGENEIC PEPTIDES | |
| DE60028396T2 (en) | METHOD FOR THE PRODUCTION OF A COMPOSITION THROUGH EXTRACTION OF PEARL MOTT AND ITS COSMETIC AND DERMATOLOGICAL USE | |
| DE20115753U1 (en) | Soluble collagens | |
| DE69619860T2 (en) | METHOD FOR PRODUCING ACTIVE MOTHER-OF-PEARL SUBSTANCES, RESULTING PRODUCTS, SUITABLE FOR MEDICAL APPLICATIONS | |
| DE4125400C2 (en) | Use of insoluble collagen for the treatment of degenerative, non-inflammatory joint processes | |
| DE10010113A1 (en) | Isolation of collagen by extraction from sponge, giving product having cyclooxygenase inhibiting activity, useful for treating inflammatory diseases such as arthritis or skin inflammation | |
| DE1071716T1 (en) | METHOD FOR CONCENTRATING A PROTEIN WITH DISEASE-RELATED INFORMATION | |
| WO1997035873A2 (en) | Peptides with antiproliferative properties | |
| RU2104702C1 (en) | Method of preparing the biologically active polypeptide complex normalizing brain functions from animal raw, pharmacological composition and its using | |
| DE69424690T2 (en) | METHOD FOR PRODUCING COLLAGEN FROM CNIDARIANS AND CORRESPONDING COSMETIC COMPOSITIONS | |
| Schofield et al. | Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: A comparison with utrophin and the apo‐dystrophins | |
| EP3797787B1 (en) | Cyclic amyloid-beta binding peptides and use of same | |
| Alsook et al. | Characterization of collagen fibrils after equine suspensory ligament injury: an ultrastructural and biochemical approach | |
| DE69224741T2 (en) | THE BONE STRENGTHENING FACTOR AND FOOD AND DRINKS THAT CONTAIN THIS FACTOR | |
| DE69531150T2 (en) | USE OF BIOPOLYMERS FOR THE TREATMENT OF THE MUSCLES | |
| RU2275924C2 (en) | Method for preparing complex of biologically active polypeptides for normalization of brain function and pharmaceutical agent based on thereof | |
| DE60319093T2 (en) | METHOD OF ISOLATING AN INTESTILANE CHOLESTERIN BIND PROTEIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 20020214 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20041220 |
|
| R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20070927 |
|
| R152 | Utility model maintained after payment of third maintenance fee after eight years |
Effective date: 20091021 |
|
| R071 | Expiry of right | ||
| R071 | Expiry of right |